Sign inJoin waitlistJoin the waitlist

Lucia Masarova

Associate Professor, Leukemia Department · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2015
Hematology
2012–2013
National Cancer Institute
2007–2012
National Cancer Institute Bratislava
2007–2010
Doctor of Medicine
2003–2007

Research

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Journal of Clinical Oncology · 2021 · 294 citations
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
The Lancet Haematology · 2020 · 280 citations
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
Blood · 2017 · 196 citations

Hagop Kantarjian
69 papers
Naval Daver
64 papers
SV
Srdan Verstovsek
62 papers
Naveen Pemmaraju
59 papers
Tapan Kadia
56 papers
Elias Jabbour
51 papers
GB
Gautam Borthakur
51 papers
Prithviraj Bose
50 papers
Guillermo Garcia-Manero
49 papers
Courtney DiNardo
46 papers
Nicholas Short
40 papers
KS
Koji Sasaki
34 papers

Clinical trials

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2024–2031
PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2019
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2005–2025
Pegasys® in Patients With Myeloproliferative Diseases
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2005–2023